Bcl-2 confers survival in cisplatin treated cervical cancer cells: circumventing cisplatin dose-dependent toxicity and resistance

BACKGROUND: Cisplatin is the main chemotherapeutic drug for the treatment of cervical cancers, however resistance to cisplatin is increasingly common and therefore has limited the efficacy and use of this drug in the clinic. Dose-dependent toxicity poses an additional challenge since patients suffer...

Descripción completa

Detalles Bibliográficos
Autores principales: Leisching, Gina, Loos, Benjamin, Botha, Matthys, Engelbrecht, Anna-Mart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4608303/
https://www.ncbi.nlm.nih.gov/pubmed/26474854
http://dx.doi.org/10.1186/s12967-015-0689-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4608303/
https://www.ncbi.nlm.nih.gov/pubmed/26474854
http://dx.doi.org/10.1186/s12967-015-0689-4

Ejemplares similares